Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
27.31
+0.19 (0.70%)
May 4, 2026, 11:18 AM EDT - Market open
Immunovant Market Cap
Immunovant has a market cap or net worth of $5.56 billion as of May 4, 2026. Its market cap has increased by 120.51% in one year.
Market Cap
5.56B
Enterprise Value
4.54B
1-Year Change
120.51%
Ranking
Category
Stock Price
$27.31
Market Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $5.56B, an increase of 4,369.12%. That is a compound annual growth rate of 73.92%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 1, 2026 | 5.52B | 7.14% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Apogee Therapeutics | 6.03B |
| Spyre Therapeutics | 5.99B |
| Mirum Pharmaceuticals | 5.89B |
| CG Oncology | 5.83B |
| Rhythm Pharmaceuticals | 5.59B |
| Scholar Rock Holding | 5.53B |
| Corcept Therapeutics | 5.52B |
| Xenon Pharmaceuticals | 5.42B |